The six subtypes were termed according to their biological characteristics as follows: C1 (CINImmuneDown), C2 (dMMR), C3 (KRASm: KRAS-mutant), C4 (CSC: cancer stem cell), C5 (CINWntUp) and C6 (CINnormL The subtypes were finally categorized by two distinct groups: a poor-prognosis group (‘C4C6′: C4 and C6), and all other subtypes as the good-prognosis (‘Others’: C1, C2, C3 and C5), corresponding with the prognostic difference. This evidence concerns the gene KRAS and cancer.